Hidenobu Ishii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hidenobu Ishii has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Koichi Azuma
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan
4 shared publications - Kazuhiko Yamada
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
3 shared publications Takaaki Tokito
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine
2 shared publicationsTomoaki Hoshino
Department of Respiratory Medicine, Kurume University
2 shared publicationsHiroaki Takeoka
National Hospital Organization Kyushu Medical Center
1 shared publication- Kazuko Matsunaga
Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
1 shared publication
Latest Publications
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii97
Retrospective analysis between PD-L1 expression and prognosis for stage III non-small cell lung cancer patients
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii97
Retrospective analysis between PD-L1 expression and prognosis for stage III non-small cell lung cancer patients
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii138
Noninvasive detection of acquired T790M mutation in NSCLC patients treated with EGFR-TKI using digital PCR of plasma
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii138
Noninvasive detection of acquired T790M mutation in NSCLC patients treated with EGFR-TKI using digital PCR of plasma
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii125
A multicenter phase II study of S-1 plus bevacizumab in patients with previously treated non-squamous NSCLC
Background: The additional effects of bevacizumab (B) as first-line chemotherapy for non-squamous non-small cell lung cancer (Non-sq NSCLC) have been established. However, the efficacy of B in a second-line setting or further has not been clarified. It has recently become clear that S-1 (S), an oral fluoropyrimidine, is effective for advanced NSCLC. Furthermore, preclinical findings have suggested that the combination of S plus B is a promising treatment option.
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii125
A multicenter phase II study of S-1 plus bevacizumab in patients with previously treated non-squamous NSCLC
Background: The additional effects of bevacizumab (B) as first-line chemotherapy for non-squamous non-small cell lung cancer (Non-sq NSCLC) have been established. However, the efficacy of B in a second-line setting or further has not been clarified. It has recently become clear that S-1 (S), an oral fluoropyrimidine, is effective for advanced NSCLC. Furthermore, preclinical findings have suggested that the combination of S plus B is a promising treatment option.
- 1 April 2015
- Published by Elsevier in European Journal of Radiology
- Vol. 84 (4) , 726-731
Paired maximum inspiratory and expiratory plain chest radiographs for assessment of airflow limitation in chronic obstructive pulmonary disease
- 1 April 2015
- Published by Elsevier in European Journal of Radiology
- Vol. 84 (4) , 726-731
Paired maximum inspiratory and expiratory plain chest radiographs for assessment of airflow limitation in chronic obstructive pulmonary disease